Company Overview and News

34
Market Update: PSU banks push Nifty higher led by BoB, PNB; RIL, GAIL up 1-3%, PC Jeweller zooms 38%

2018-05-07 moneycontrol
The Indian equity market extended gains and was trading on a positive note on Monday afternoon with the Nifty gaining 79 points and was trading at a shade below 10,700 at 10,697 while the Sensex was up 248 points or 0.71 percent.
500325 532714 539437 532483 534816 GAILF CLNDY RLNIY SBAZ TVSMOTOR AXB 501425 APOLLOTYRE YYBKY AYRQY BBTC CNRYY AXBA GAILY 534809 TCS HINDPETRO PCJEWELLER 500104 CANBK COALINDIA BHRYY 533150 RELIANCE 533273 TTNQY 533278 532215 532343 532540 IDFCBANK 532461 AXISBANK RIGD INFRATEL KEC YESBANK HINDALCO 500877 IBN 532648 AXBKY HNDNF ICICIBANK OBZIY GODREJPROP OBEROIRLTY PNJZY 532174 501455 PNB GREAVESCOT 500440

39
Market Update: Axis Bank, Hindalco up 2-3% while Lupin sheds 3%; Jubilant Food hits new 52-week high

2018-05-07 moneycontrol
The Indian equity market extended loses was trading on a negative note on Monday afternoon with the Nifty gaining 36 points was trading at 10,654 while the Sensex was up 96 points or 0.28 percent.
531500 539437 532960 532483 EICHERMOT CLNDY SBAZ RAJESHEXPO AXB 501425 BBTC CNRYY AXBA TATASTEEL TATLY 534809 TCS HINDPETRO PCJEWELLER 500104 CANBK COALINDIA 533150 533273 TTNQY 533278 IDBLZ 532215 505200 500470 532540 IDFCBANK 532461 AXISBANK ECQRY HINDALCO IBVENTURES IBN AXBKY HNDNF ICICIBANK OBZIY GODREJPROP TTST OBEROIRLTY PNJZY 532174 PNB 500440

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...